Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Nucleic Acid
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Argo Biopharma Australia Pty Ltd
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for BW-20507](https://pryzm-maps.s3.us-west-2.amazonaws.com/8current_maps.png)
Countries in Clinic: Australia
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Hepatitis B, Chronic|Intestinal Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ACTRN12623000708651 | P2 |
Recruiting |
Intestinal Diseases|Hepatitis B, Chronic |
2023-11-30 |
|
ACTRN12623000709640 | P2 |
Recruiting |
Hepatitis B, Chronic|Intestinal Diseases |
2023-11-30 |